United Therapeutics

UTHR

Market cap $22.7B

UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.

United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved.

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.

United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of th.

Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics' wholly.

While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay after declaring, there is no hard requirement for companies to spend the buyback capacity they authorize.

Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of companies is capitalizing on space, which allows for complex chemical processes that gravity makes impossible on Earth.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?